ASYMMETRYBETA
Loading MRNA...
Moderna Inc.MRNAAs of 31 July 2026
Trailing (TTM)
Price to earnings·
Price to sales·
Price to book·
Price to op. cash flow·
Price to free cash flow·
Forward P/S (NTM)
Forward P/S (Y1)·
Forward P/S (Y2)·
Forward P/S (Y3)·
Forward P/S (Y4)·
Forward P/S (Y5)·
Forward P/E (NTM)
Forward P/E (Y1)·
Forward P/E (Y2)·
Forward P/E (Y3)·
Forward P/E (Y4)·
Forward P/E (Y5)·
Forward EV/EBIT (NTM)
Forward EV/EBIT (Y1)·
Forward EV/EBIT (Y2)·
Forward EV/EBIT (Y3)·
Forward EV/EBIT (Y4)·
Forward EV/EBIT (Y5)·
−300−1500+150+300
+69
PositiveNegative
Negative skew
Valuation+4
CheapExpensive
Emotion−34
FearGreed
Fundamentals−100
WeakStrong
Valuation

Is Moderna Inc. undervalued or overvalued?

Where Moderna Inc. (MRNA) trades across 21 valuation metrics, from price-to-sales and forward P/E to book and cash-flow multiples, each ranked against its own five-year history rather than a broad sector average, so you can see whether it is genuinely cheap or expensive on its own terms. Information, not advice.

Moderna Inc.MRNALast 5 years
V—E—F—A—
——
MRNA priceasymmetryquant.com
A Asymmetry—
V Valuation—
E Emotion—
F Fundamentals—